Creating a new treatment for bronchopulmonary dysplasia in preterm infants
Official title: Development of a systems pharmacology agent for treatment of bronchopulmonary dysplasia
Funded at Reneurogen, LLC · NIH-10888168 · Data updated 2026-11-12
This study is testing a new treatment for bronchopulmonary dysplasia (BPD) in preterm babies, using a special compound that helps reduce lung stress and inflammation, with the hope of making their lungs healthier and improving their overall well-being.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Reneurogen, LLC NIH-funded |
| Lab location | 1 site (Elm Grove, United States) |
| Project start | June 15, 2023 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,861,772 |
| NIH project number | 5R44HL166018-02 |
| Project ID | NIH-10888168 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are preterm infants at risk of developing bronchopulmonary dysplasia.
✕Less likely to help
Patients who are not preterm or do not have bronchopulmonary dysplasia may not benefit from this research.
What this research studies
This research focuses on developing a novel treatment for bronchopulmonary dysplasia (BPD), a serious lung condition affecting preterm infants. The approach involves using a bioengineered tripeptide called N-acetyl-lysyltyrosylcysteine amide (KYC) that targets oxidative stress and inflammation in the lungs. By conducting preclinical studies on safety and effectiveness, the research aims to gather essential data for FDA approval. If successful, this treatment could significantly improve lung health and overall outcomes for affected infants.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that improves lung growth and survival rates in preterm infants with bronchopulmonary dysplasia.
How similar studies have gone: Preliminary studies have shown promise with similar approaches, indicating potential for success in this novel treatment.
Where this research is happening
-
Reneurogen, LLC
Elm Grove, United States Active
Researchers
- Principal investigator: Naylor, Stephen — Reneurogen, LLC
- Study coordinator: Naylor, Stephen
Related research
Other NIH-funded projects on the same topics.
-
Role of uneven lung growth in chronic lung disease from birth to adulthood
This grant explores how mismatched growth of airways, airspaces, and blood vessels during early life might lead to lasting lung problems in bronchopulmonary dysplasia and how that affects people over time.
-
Regulatory T Cells and Lung Disease-Related High Blood Pressure in Adults
This project studies how a type of immune cell called regulatory T cells may influence inflammation and blood vessel changes in lung disease, with potential relevance to adults who have vascular issues in their lungs.
-
Understanding how breathing effort in premature babies with lung disease comes from different lung problems
A research project aims to create a patient-specific tool to measure how different features of bronchopulmonary dysplasia contribute to the struggle to breathe in premature infants.
-
Role of LKB1 in reduced lung blood vessel growth in BPD
Aims to understand how a cellular regulator (LKB1) affects blood vessel formation in the lungs of preterm infants at risk for bronchopulmonary dysplasia.
-
A new approach to prevent bronchopulmonary dysplasia in preterm infants
A new treatment strategy aimed at improving lung development in premature babies at risk for bronchopulmonary dysplasia.
-
L-Citrulline for BPD-related Pulmonary Hypertension in Preterm Babies
A first-in-human study will test safe and effective doses of L-citrulline given by mouth to stability-preterm infants at risk for lung blood pressure problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.